Literature DB >> 26771848

Genomic landscape of intracranial meningiomas.

Wenya Linda Bi1,2, Malak Abedalthagafi3, Peleg Horowitz1, Pankaj K Agarwalla4,2, Yu Mei1, Ayal A Aizer5, Ryan Brewster3, Gavin P Dunn6, Ossama Al-Mefty1, Brian M Alexander5, Sandro Santagata3, Rameen Beroukhim2, Ian F Dunn1.   

Abstract

Meningiomas are the most common primary intracranial neoplasms in adults. Current histopathological grading schemes do not consistently predict their natural history. Classic cytogenetic studies have disclosed a progressive course of chromosomal aberrations, especially in high-grade meningiomas. Furthermore, the recent application of unbiased next-generation sequencing approaches has implicated several novel genes whose mutations underlie a substantial percentage of meningiomas. These insights may serve to craft a molecular taxonomy for meningiomas and highlight putative therapeutic targets in a new era of rational biology-informed precision medicine.

Entities:  

Keywords:  MAPK = mitogen-activated protein kinase; NF2 = neurofibromatosis Type 2; PI3K = phosphoinositide-3-kinase; genomics; hpf = high-power field; mTOR = mammalian target of rapamycin; meningioma; molecular taxonomy; oncology; precision medicine; targeted therapy; tumor classification; tumor progression

Mesh:

Year:  2016        PMID: 26771848     DOI: 10.3171/2015.6.JNS15591

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  29 in total

1.  SMO mutation status defines a distinct and frequent molecular subgroup in olfactory groove meningiomas.

Authors:  Julien Boetto; Franck Bielle; Marc Sanson; Matthieu Peyre; Michel Kalamarides
Journal:  Neuro Oncol       Date:  2017-03-01       Impact factor: 12.300

2.  Multiplatform profiling of meningioma provides molecular insight and prioritization of drug targets for rational clinical trial design.

Authors:  Richard G Everson; Yuuri Hashimoto; Jacob L Freeman; Tiffany R Hodges; Jason Huse; Shouhao Zhou; Joanne Xiu; David Spetzler; Nader Sanai; Lyndon Kim; Santosh Kesari; Andrew Brenner; Franco De Monte; Amy Heimberger; Shaan M Raza
Journal:  J Neurooncol       Date:  2018-05-30       Impact factor: 4.130

3.  Clinical features, surgical management, and prognostic factors of secretory meningiomas: a single-center case series of 149 patients.

Authors:  Xiaogang Tao; Kun Wang; Jinqian Dong; Zonggang Hou; Zhen Wu; Junting Zhang; Baiyun Liu
Journal:  J Neurooncol       Date:  2017-11-15       Impact factor: 4.130

4.  WHO grade I meningiomas: classification-tree for prognostic factors of survival.

Authors:  Jean-Michel Lemée; Holger Joswig; Michele Da Broi; Marco Vincenzo Corniola; David Scheie; Karl Schaller; Eirik Helseth; Torstein R Meling
Journal:  Neurosurg Rev       Date:  2019-06-10       Impact factor: 3.042

5.  Value of K i -67 Labeling Index in Predicting Recurrence of WHO Grade I Cranial Base Meningiomas.

Authors:  Jose Gabrielle Matias; Ignacio Jusue-Torres; Brendan Martin; Ankush Bajaj; Ewa Borys; Edward Melian; Kevin Barton; Douglas E Anderson; Vikram C Prabhu
Journal:  J Neurol Surg B Skull Base       Date:  2018-09-06

6.  Distinct clinical outcome of microcystic meningioma as a WHO grade 1 meningioma subtype.

Authors:  Leihao Ren; Lingyang Hua; Zhongyuan Bao; Hiroaki Wakimoto; Ye Gong; Jiaojiao Deng; Daijun Wang; Jiawei Chen; Hong Chen; Tareq A Juratli
Journal:  J Neurooncol       Date:  2022-05-25       Impact factor: 4.130

7.  Skull Base Meningiomas in Patients with Neurofibromatosis Type 2: An International Multicenter Study Evaluating Stereotactic Radiosurgery.

Authors:  Henry Ruiz-Garcia; Daniel M Trifiletti; Nasser Mohammed; Yi-Chieh Hung; Zhiyuan Xu; Tomas Chytka; Roman Liscak; Manjul Tripathi; David Arsanious; Christopher P Cifarelli; Marco Perez Caceres; David Mathieu; Herwin Speckter; Gautam U Mehta; Gregory P Lekovic; Jason P Sheehan
Journal:  J Neurol Surg B Skull Base       Date:  2021-01-19

8.  Comprehensive Molecular Profiling Identifies FOXM1 as a Key Transcription Factor for Meningioma Proliferation.

Authors:  Harish N Vasudevan; Steve E Braunstein; Joanna J Phillips; Melike Pekmezci; Bryan A Tomlin; Ashley Wu; Gerald F Reis; Stephen T Magill; Jie Zhang; Felix Y Feng; Theodore Nicholaides; Susan M Chang; Penny K Sneed; Michael W McDermott; Mitchel S Berger; Arie Perry; David R Raleigh
Journal:  Cell Rep       Date:  2018-03-27       Impact factor: 9.423

9.  Convexity Meningiomas in Patients with Neurofibromatosis Type 2: Long-Term Outcomes After Gamma Knife Radiosurgery.

Authors:  Henry Ruiz-Garcia; Daniel M Trifiletti; Nasser Mohammed; Yi-Chieh Hung; Zhiyuan Xu; Tomas Chytka; Roman Liscak; Manjul Tripathi; David Arsanious; Christopher P Cifarelli; Marco Perez Caceres; David Mathieu; Herwin Speckter; Gregory P Lekovic; Gautam U Mehta; Jason P Sheehan
Journal:  World Neurosurg       Date:  2020-11-03       Impact factor: 2.104

10.  Sarcomatous Meningioma: Diagnostic Pitfalls and the Utility of Molecular Testing.

Authors:  Calixto-Hope G Lucas; Patrick Devine; David A Solomon; Caterina Giannini; Guido Reifenberger; Sonika Dahiya; Dario Caccamo; Arie Perry
Journal:  J Neuropathol Exp Neurol       Date:  2021-09-10       Impact factor: 3.148

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.